Risks of Lynch syndrome cancers for MSH6 mutation carriers
- PMID: 20028993
- PMCID: PMC2815724
- DOI: 10.1093/jnci/djp473
Risks of Lynch syndrome cancers for MSH6 mutation carriers
Abstract
Background: Germline mutations in MSH6 account for 10%-20% of Lynch syndrome colorectal cancers caused by hereditary DNA mismatch repair gene mutations. Because there have been only a few studies of mutation carriers, their cancer risks are uncertain.
Methods: We identified 113 families of MSH6 mutation carriers from five countries that we ascertained through family cancer clinics and population-based cancer registries. Mutation status, sex, age, and histories of cancer, polypectomy, and hysterectomy were sought from 3104 of their relatives. Age-specific cumulative risks for carriers and hazard ratios (HRs) for cancer risks of carriers, compared with those of the general population of the same country, were estimated by use of a modified segregation analysis with appropriate conditioning depending on ascertainment.
Results: For MSH6 mutation carriers, the estimated cumulative risks to ages 70 and 80 years, respectively, were as follows: for colorectal cancer, 22% (95% confidence interval [CI] = 14% to 32%) and 44% (95% CI = 28% to 62%) for men and 10% (95% CI = 5% to 17%) and 20% (95% CI = 11% to 35%) for women; for endometrial cancer, 26% (95% CI = 18% to 36%) and 44% (95% CI = 30% to 58%); and for any cancer associated with Lynch syndrome, 24% (95% CI = 16% to 37%) and 47% (95% CI = 32% to 66%) for men and 40% (95% CI = 32% to 52%) and 65% (95% CI = 53% to 78%) for women. Compared with incidence for the general population, MSH6 mutation carriers had an eightfold increased incidence of colorectal cancer (HR = 7.6, 95% CI = 5.4 to 10.8), which was independent of sex and age. Women who were MSH6 mutation carriers had a 26-fold increased incidence of endometrial cancer (HR = 25.5, 95% CI = 16.8 to 38.7) and a sixfold increased incidence of other cancers associated with Lynch syndrome (HR = 6.0, 95% CI = 3.4 to 10.7).
Conclusion: We have obtained precise and accurate estimates of both absolute and relative cancer risks for MSH6 mutation carriers.
Figures
References
-
- Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81(2):214–218. - PubMed
-
- Southey MC, Jenkins MA, Mead L, et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol. 2005;23(27):6524–6532. - PubMed
-
- Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer) N Engl J Med. 2005;352(18):1851–1860. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 CA074799/CA/NCI NIH HHS/United States
- UO1 CA074800/CA/NCI NIH HHS/United States
- R01-CA67941/CA/NCI NIH HHS/United States
- UO1 CA074806/CA/NCI NIH HHS/United States
- U01 CA097735/CA/NCI NIH HHS/United States
- U01 CA074806/CA/NCI NIH HHS/United States
- U01 CA074800/CA/NCI NIH HHS/United States
- G0000657-53203/MRC_/Medical Research Council/United Kingdom
- CZB/4/449/CSO_/Chief Scientist Office/United Kingdom
- CA16058/CA/NCI NIH HHS/United States
- K/OPR/2/2/D333/CSO_/Chief Scientist Office/United Kingdom
- UO1 CA074799/CA/NCI NIH HHS/United States
- CA67941/CA/NCI NIH HHS/United States
- MC_U127527198/MRC_/Medical Research Council/United Kingdom
- U01 CA074794/CA/NCI NIH HHS/United States
- UO1 CA074794/CA/NCI NIH HHS/United States
- CA-95-011/CA/NCI NIH HHS/United States
- U01 CA074783/CA/NCI NIH HHS/United States
- C348/A8896/CRUK_/Cancer Research UK/United Kingdom
- UO1 CA097735/CA/NCI NIH HHS/United States
- UO1 CA074783/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous